Liposomal Cisplatin Safe for Patients with Renal Insufficiency
Liposomal cisplatin (Nanoplatin®), a chemotherapy drug still in clinical trials, does not cause damage to the kidneys and appears to provide at least equal anti-cancer effects as cisplatin (Platinol®) among cancer patients with renal insufficiency. These results were recently presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Cisplatin (Platinol®) is a commonly used and effective chemotherapy agent for several types of cancers. It is excreted by the kidneys and can cause extensive damage to the kidneys, particularly in cumulative doses. Therefore, patients with renal insufficiency often are not able to receive treatment with cisplatin.
Liposomal cisplatin is a newer formulation of cisplatin developed so that the chemotherapy agent is delivered to the tumor and the active formulation does not accumulate in the kidneys and cause damage.
To further evaluate the safety of liposomal cisplatin, researchers from Greece conducted a study that included 40 patients who were treated with liposomal cisplatin plus gemcitabine (Gemzar®): 16 with non-small cell lung cancer, 14 with bladder cancer and 10 with gastrointestinal tract cancers. All patients had renal insufficiency prior to therapy and had serum creatinine tested before each treatment and one week following treatment to determine the safety of this regimen on the kidneys.
- No patient experienced an elevation in serum creatinine, a strong indicator that treatment did no damage to kidneys.
- The only serious side effect of this regimen was fatigue.
As prior studies evaluating liposomal cisplatin have demonstrated its comparable efficacy to cisplatin, these results provide evidence in regards to safety and its potential use in patients with cancer with renal insufficiency. Liposomal cisplatin is not yet approved by the FDA, but continues to advance in clinical trials in the United States and Europe.
Reference: Stathopoulos G, Rigatos S, Stathopoulos J, et al. Liposomal cisplatin in cancer patients with renal failure. Paper presented at the 2011 annual meeting of the American Society of Clinical Oncology. July 3-7, 2011. Chicago, IL. Abstract 7072.
Copyright © 2011 CancerConsultants. All Rights Reserved.